Thus, these antibodies which attack the PD‐L1/PD‐1 axis alone [4, 5] or combined with chemotherapy in first‐line have significantly prolonged median overall survival of metastatic NSCLC patients [6]. Here, CD274 is linked to non-small cell lung carcinoma.